The New England journal of medicine, 2023-04, Vol.388 (15), p.1353-1364
- Nissen, Steven E.
- Lincoff, A. Michael
- Brennan, Danielle
- Ray, Kausik K.
- Mason, Denise
- Kastelein, John J.P.
- Thompson, Paul D.
- Libby, Peter
- Cho, Leslie
- Plutzky, Jorge
- Bays, Harold E.
- Moriarty, Patrick M.
- Menon, Venu
- Grobbee, Diederick E.
- Louie, Michael J.
- Chen, Chien-Feng
- Li, Na
- Bloedon, LeAnne
- Robinson, Paula
- Horner, Maggie
- Sasiela, William J.
- McCluskey, Jackie
- Davey, Deborah
- Fajardo-Campos, Pedro
- Petrovic, Predrag
- Fedacko, Jan
- Zmuda, Witold
- Lukyanov, Yury
- Nicholls, Stephen J.
2023
Details
- Autor(en) / Beteiligte
- Nissen, Steven E.
- Lincoff, A. Michael
- Brennan, Danielle
- Ray, Kausik K.
- Mason, Denise
- Kastelein, John J.P.
- Thompson, Paul D.
- Libby, Peter
- Cho, Leslie
- Plutzky, Jorge
- Bays, Harold E.
- Moriarty, Patrick M.
- Menon, Venu
- Grobbee, Diederick E.
- Louie, Michael J.
- Chen, Chien-Feng
- Li, Na
- Bloedon, LeAnne
- Robinson, Paula
- Horner, Maggie
- Sasiela, William J.
- McCluskey, Jackie
- Davey, Deborah
- Fajardo-Campos, Pedro
- Petrovic, Predrag
- Fedacko, Jan
- Zmuda, Witold
- Lukyanov, Yury
- Nicholls, Stephen J.
- Titel
- Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
- Ist Teil von
- The New England journal of medicine, 2023-04, Vol.388 (15), p.1353-1364
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2023
- Link zum Volltext
- Quelle
- Electronic Journals Library
- Beschreibungen/Notizen
- In this randomized trial, statin-intolerant patients with, or at high risk for, CVD received bempedoic acid or placebo. Bempedoic acid reduced LDL cholesterol and the risk of cardiovascular events.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2215024Titel-ID: cdi_proquest_miscellaneous_2783792632
- Format
- –
- Schlagworte
- Acids, Administration, Oral, ATP citrate lyase, Cardiology, Cardiovascular diseases, Cardiovascular Diseases - drug therapy, Cardiovascular Diseases - epidemiology, Cardiovascular Diseases - prevention & control, Cardiovascular Diseases - surgery, Cerebral infarction, Cholesterol, Clinical Medicine, Clinical Medicine General, Coronary Disease, Creatinine, Death, Double-Blind Method, Fatty Acids - administration & dosage, Fatty Acids - adverse effects, Fatty Acids - therapeutic use, FDA approval, Gout, Heart attacks, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects, Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use, Hypolipidemic Agents - administration & dosage, Hypolipidemic Agents - adverse effects, Hypolipidemic Agents - therapeutic use, Laboratories, Lipids, Low density lipoprotein, Myocardial Infarction, Myocardial Infarction - epidemiology, Myocardial Infarction - prevention & control, Myocardial Revascularization, Outpatient-Based Clinical Medicine, Patients, Placebos, Prevention, Statins, Statistical analysis, Stroke, Stroke - epidemiology, Stroke - prevention & control, Uric acid